Pelacarsen clinical trials
Also written TQJ230.
Includes 4 studies of Pelacarsen sodium.
ClinicalTrials.gov finds 14 studies for pelacarsen. How that becomes 17 here
Every study that search finds has been read, to see whether and how it gives pelacarsen. ClinicalTrials.gov counts as of Nov 16, 2026. How drug pages count
- 14Found by its intervention search · See all 14 hereIt also reads titles, arm labels, keywords and descriptions, and counts the drug’s other names. Of these, 13 name it in an intervention entry. The counts it shows beside each synonym overlap: a study writing two names counts under both.
- +4Give it under a name that search misses: a biosimilar’s code or a misspelling
- 18Give pelacarsen to participants
- −1Observe patients on it, or give it outside a trial
- 17Test it: the count on this site
Get an email when these change. Save the pelacarsen studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
17 studies that test it; most in 2017 (3)
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2017 | 3 |
| 2018 | 2 |
| 2019 | 1 |
| 2021 | 2 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 2 |
| 2025 | 2 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 16 · Other 1
Novartis Pharmaceuticals (10) · Akcea Therapeutics (4) · Ionis Pharmaceuticals, Inc. (2) · University Medical Centre Ljubljana (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses pelacarsen has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Some give it without naming it in an intervention entry: those were found by reading the record.
Testing it · 17
- A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve StenosisRecruitingPhase 2Novartis PharmaceuticalsNCT05646381On calcific aortic valve stenosisWritten as Pelacarsen (TQJ230) 80mgReport a problem
- An Open Label Extension (OLE) Study to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)TerminatedPhase 3Novartis PharmaceuticalsNCT05900141Open-label extension after the apheresis studyWritten as PelacarsenReport a problem
- Pelacarsen Roll-over Extension ProgramActive, not recruitingPhase 3Novartis PharmaceuticalsNCT06875973Roll-over extension programmeWritten as Pelacarsen (TQJ230)Report a problem
- Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVDActive, not recruitingPhase 3Novartis PharmaceuticalsNCT06813911With background inclisiran in high Lp(a)Written as PelacarsenReport a problem
- An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)Active, not recruitingPhase 3Novartis PharmaceuticalsNCT07517263Open-label extension after HORIZONWritten as Pelacarsen (TQJ230)Report a problem
- Lp(a) Lowering Study of Pelacarsen (TQJ230) in Patients in the US With Elevated Lp(a) and Recent ACS (STEMI/NSTEMI) - Lp(a)FRONTIERS PEARLWithdrawnPhase 3Novartis PharmaceuticalsNCT07625306After a recent acute coronary syndrome (Lp(a)FRONTIERS PEARL)Written as PelacarsenReport a problem
- Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVDCompletedPhase 3Novartis PharmaceuticalsNCT04023552On major cardiovascular events (Lp(a)HORIZON)Written as TQJ230Report a problem
- Lp(a) Lowering Study of Pelacarsen (TQJ230) in US Black/African American and Hispanic Participants With Elevated Lp(a) and Established ASCVDCompletedPhase 3Novartis PharmaceuticalsNCT06267560In Black and Hispanic US participants with high Lp(a)Written as TQJ230Report a problem
- A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Rate of Weekly Lipoprotein Apheresis Sessions in Patients With Hyperlipoproteinemia(a) and Established Cardiovascular Disease in GermanyCompletedPhase 3Novartis PharmaceuticalsNCT05305664On weekly lipoprotein apheresis sessionsWritten as Pelacarsen (TQJ230) 80 mg s.c.Report a problem
- Study to Assess the Pharmacokinetics of Pelacarsen (TQJ230) in Participants With Mild Hepatic Impairment Compared to Matched Healthy ParticipantsCompletedPhase 1Novartis PharmaceuticalsNCT05026996In mild hepatic impairmentWritten as PelacarsenReport a problem
- A Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Pelacarsen (ISIS 681257) in Healthy Japanese ParticipantsCompletedPhase 1Ionis Pharmaceuticals, Inc.NCT05337878In healthy Japanese participantsWritten as PelacarsenReport a problem
- Influence of Pelacarsen on Patients After Myocardial Infarction With High Lp(a) Values (PEMILA)WithdrawnNot applicableUniversity Medical Centre LjubljanaNCT04993664After myocardial infarction with high Lp(a) (PEMILA)Written as Pelacarsen (TQJ230)Report a problem
- Phase 2 Study of ISIS 681257 (AKCEA-APO(a)-LRx) in Participants With Hyperlipoproteinemia(a) and Cardiovascular DiseaseCompletedPhase 2Akcea TherapeuticsNCT03070782Dose finding in high Lp(a) with cardiovascular diseaseWritten as ISIS 681257Report a problem
- Study of ISIS 681257 in Patients With Renal Impairment Compared to Healthy PatientsCompletedPhase 1Akcea TherapeuticsNCT03506854In kidney impairment compared with healthy peopleWritten as ISIS 681257Report a problem
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS APO(a)-LRx in Healthy Volunteers With Elevated Lipoprotein(a)CompletedPhase 1Ionis Pharmaceuticals, Inc.NCT02414594First in human, in healthy volunteers with high Lp(a)Written as IONIS-APO(a)-LRxReport a problem
- Drug-drug Interaction Study to Evaluate the Effect of ISIS 681257 on WarfarinCompletedPhase 1Akcea TherapeuticsNCT03426033Its effect on warfarin in healthy peopleWritten as ISIS 681257Report a problem
- Drug-drug Interaction Study to Evaluate the Effect of ISIS 681257 on ClopidogrelCompletedPhase 1Akcea TherapeuticsNCT03392051Its effect on clopidogrel in healthy peopleWritten as ISIS 681257Report a problem
Tested on its own · 14 — no other medicine in its arm
- A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve StenosisRecruitingPhase 2Novartis PharmaceuticalsNCT05646381On calcific aortic valve stenosisWritten as Pelacarsen (TQJ230) 80mgReport a problem
- An Open Label Extension (OLE) Study to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)TerminatedPhase 3Novartis PharmaceuticalsNCT05900141Open-label extension after the apheresis studyWritten as PelacarsenReport a problem
- Pelacarsen Roll-over Extension ProgramActive, not recruitingPhase 3Novartis PharmaceuticalsNCT06875973Roll-over extension programmeWritten as Pelacarsen (TQJ230)Report a problem
- An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)Active, not recruitingPhase 3Novartis PharmaceuticalsNCT07517263Open-label extension after HORIZONWritten as Pelacarsen (TQJ230)Report a problem
- Lp(a) Lowering Study of Pelacarsen (TQJ230) in Patients in the US With Elevated Lp(a) and Recent ACS (STEMI/NSTEMI) - Lp(a)FRONTIERS PEARLWithdrawnPhase 3Novartis PharmaceuticalsNCT07625306After a recent acute coronary syndrome (Lp(a)FRONTIERS PEARL)Written as PelacarsenReport a problem
- Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVDCompletedPhase 3Novartis PharmaceuticalsNCT04023552On major cardiovascular events (Lp(a)HORIZON)Written as TQJ230Report a problem
- Lp(a) Lowering Study of Pelacarsen (TQJ230) in US Black/African American and Hispanic Participants With Elevated Lp(a) and Established ASCVDCompletedPhase 3Novartis PharmaceuticalsNCT06267560In Black and Hispanic US participants with high Lp(a)Written as TQJ230Report a problem
- A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Rate of Weekly Lipoprotein Apheresis Sessions in Patients With Hyperlipoproteinemia(a) and Established Cardiovascular Disease in GermanyCompletedPhase 3Novartis PharmaceuticalsNCT05305664On weekly lipoprotein apheresis sessionsWritten as Pelacarsen (TQJ230) 80 mg s.c.Report a problem
- Study to Assess the Pharmacokinetics of Pelacarsen (TQJ230) in Participants With Mild Hepatic Impairment Compared to Matched Healthy ParticipantsCompletedPhase 1Novartis PharmaceuticalsNCT05026996In mild hepatic impairmentWritten as PelacarsenReport a problem
- A Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Pelacarsen (ISIS 681257) in Healthy Japanese ParticipantsCompletedPhase 1Ionis Pharmaceuticals, Inc.NCT05337878In healthy Japanese participantsWritten as PelacarsenReport a problem
- Influence of Pelacarsen on Patients After Myocardial Infarction With High Lp(a) Values (PEMILA)WithdrawnNot applicableUniversity Medical Centre LjubljanaNCT04993664After myocardial infarction with high Lp(a) (PEMILA)Written as Pelacarsen (TQJ230)Report a problem
- Phase 2 Study of ISIS 681257 (AKCEA-APO(a)-LRx) in Participants With Hyperlipoproteinemia(a) and Cardiovascular DiseaseCompletedPhase 2Akcea TherapeuticsNCT03070782Dose finding in high Lp(a) with cardiovascular diseaseWritten as ISIS 681257Report a problem
- Study of ISIS 681257 in Patients With Renal Impairment Compared to Healthy PatientsCompletedPhase 1Akcea TherapeuticsNCT03506854In kidney impairment compared with healthy peopleWritten as ISIS 681257Report a problem
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS APO(a)-LRx in Healthy Volunteers With Elevated Lipoprotein(a)CompletedPhase 1Ionis Pharmaceuticals, Inc.NCT02414594First in human, in healthy volunteers with high Lp(a)Written as IONIS-APO(a)-LRxReport a problem
Tested in a combination · 3 — another drug in the study is under test too
- Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVDActive, not recruitingPhase 3Novartis PharmaceuticalsNCT06813911With background inclisiran in high Lp(a)Written as PelacarsenReport a problem
- Drug-drug Interaction Study to Evaluate the Effect of ISIS 681257 on WarfarinCompletedPhase 1Akcea TherapeuticsNCT03426033Its effect on warfarin in healthy peopleWritten as ISIS 681257Report a problem
- Drug-drug Interaction Study to Evaluate the Effect of ISIS 681257 on ClopidogrelCompletedPhase 1Akcea TherapeuticsNCT03392051Its effect on clopidogrel in healthy peopleWritten as ISIS 681257Report a problem
Observed · 1 — patients on it are followed, or it is given outside a trial
What changed recently
From the registry's own updates since Oct 18, 2026.
Stopped1
- An Open Label Extension (OLE) Study to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)TerminatedNov 10, 2026NCT05900141
Codes
What other systems call pelacarsen · ClinicalTrials.gg INT002089
- MeSH (NLM) C000730804pelacarsenOne source ClinicalTrials.gov
- UNII (FDA) LSO9H7UZ90PELACARSENOne source FDA
- NCI Thesaurus C174676PelacarsenOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000730804 | pelacarsen | One source ClinicalTrials.gov |
| UNII (FDA) | LSO9H7UZ90 | PELACARSEN | One source FDA |
| NCI Thesaurus | C174676 | Pelacarsen | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.